Plain-English translation of NCT06463743 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a pilot study testing whether —an affordable, well-known medication typically used for diabetes—might also help protect nerve cells in people with multiple sclerosis. Researchers want to understand if the medication is safe to take alongside your current MS treatments and whether it can slow the decline of nerve health over 9 months, as measured by brain imaging.
People with MS, especially older adults, currently have no treatments that directly target the nerve damage and degeneration part of the disease. Early research suggests this medication may reduce inflammation and help repair nerve cells, so doctors want to test whether it could fill this gap and offer a new way to support brain health.
You likely qualify if…
You likely don't qualify if…
You would take either the medication or a placebo pill daily for 9 months. During the study, you'll have brain MRI scans and blood work to measure how your nerve health is changing. You'll also have regular check-ins with the research team to discuss how you're tolerating the treatment and any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
State University of New York at Buffalo
Collaborators
National Center for Advancing Translational Sciences (NCATS)
Enrollment target
~30 participants
Started
September 2025
Primary completion
January 2027
Age range
55 Years – 75 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kara Patrick
State University of New York at Buffalo
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.